First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets ...

One such platform is the Virus-Like Particle (VLP) vaccine technology. While not as widely known as mRNA vaccines, Ferritin based nano platform VLP vaccines have been noted for their potential to ...

Future Virology. 2014;9(7):633-653. A second-generation L2-based HPV vaccine will face several challenges in reaching the market. Since L1 VLP vaccines are finding widespread application in the ...

The VLP vaccines have already impacted the reduction of pre-malignant lesions and genital warts, and it is expected that vaccination efforts will successfully lower the incidence of cervical ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such shot, using mRNA technology against the virus. Here’s what to know about norovirus ...

New Delhi: After prolonged request for the inclusion of the Human Papillomavirus (HPV) vaccine indicated for ... update but did not specify an exact timeline. She stated that the ministry is ...

A new experimental vaccine developed by researchers at MIT and Caltech could ... mammals may also hold the potential to spread to humans in the future. Subscribe to Technology Networks’ daily ...

Identifying bNAbs and utilizing them in vaccine technology has proven challenging, however, researchers have made multiple strides this year alone in disease areas such as COVID-19 and HIV. Today, ...

Kennedy Jr., has a long history of raising doubts about vaccines — despite decades of evidence showing they've saved millions of people from debilitating illness or death. "People forget what it ...